CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $3 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 97.8% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -275.9% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -339.1% | – | – | – |
| EPS Diluted | -0.99 | -1.35 | -1.3 | -0.71 |
| % Growth | 26.7% | -3.8% | -83.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |